Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating

A wave of tau-targeted agents is progressing through the clinic, hoping to avoid the negative results from a first-in-class trial of a tau-targeted antibody. A wave of tau-targeted agents is progressing through the clinic, hoping to avoid the negative results from a first-in-class trial of a tau-targeted antibody.

Automated summary

A new wave of tau-targeted agents is being tested in clinical trials, aiming to avoid the negative outcomes seen in the first-in-class trial of a tau-targeted antibody.